MiniMed Group (NASDAQ:MMED) Coverage Initiated by Analysts at Benchmark

Equities research analysts at Benchmark began coverage on shares of MiniMed Group (NASDAQ:MMED) in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm set a “buy” rating and a $20.00 price target on the stock. Benchmark’s price objective would suggest a potential upside of 79.21% from the company’s current price.

Several other research firms also recently issued reports on MMED. William Blair assumed coverage on MiniMed Group in a report on Tuesday, March 31st. They set an “outperform” rating on the stock. Morgan Stanley assumed coverage on MiniMed Group in a report on Tuesday, March 31st. They issued an “overweight” rating and a $19.00 target price on the stock. Citigroup assumed coverage on MiniMed Group in a report on Tuesday, March 31st. They issued a “buy” rating and a $23.00 target price on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on MiniMed Group in a report on Tuesday, March 31st. They issued a “buy” rating and a $20.00 target price on the stock. Finally, Wells Fargo & Company assumed coverage on MiniMed Group in a report on Tuesday, March 31st. They issued an “overweight” rating and a $26.00 target price on the stock. Twelve investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $22.25.

MiniMed Group Stock Performance

NASDAQ MMED opened at $11.16 on Tuesday. The business’s 50-day moving average is $14.48. MiniMed Group has a 1 year low of $11.10 and a 1 year high of $20.48.

About MiniMed Group

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.